Frontier IP Group - inSignals Neurotech receives EUR100,000 investment
REACH - non-regulatory announcement
AIM: FIPP
Frontier IP Group Plc
("Frontier IP" or the "Group")
Portfolio news - inSignals Neurotech receives €100,000 investment from
Portugal Ventures
Frontier IP, a specialist in commercialising intellectual property ("IP"), today announces that portfolio company inSignals Neurotech ("inSignals" or "the Company") has received a
The funding will be used by inSignals to accelerate the validation and development of its patented technology to aid deep brain stimulation surgery on patients suffering Parkinson's disease. It will also support validation of other applications in neurology.
In particular, it will allow the Company to expand preliminary clinical trials, strengthen its intellectual property position and grow its team. The Company was selected as a 'one to watch' in the Nature Spinoff Prize 2020 and has already received interest from potential industry partners. It is entering collaboration agreements to extend multi-centre clinical studies in
Frontier IP holds a 33 per cent equity stake in inSignals. The Company, a spin out from the Portuguese Institute for Systems and Computer Engineering, Technology and Science ("INESC TEC") with the support of São João University Hospital, part of the University of Porto, is developing wireless wearable devices to precisely measure wrist rigidity to help surgeons place brain implants more accurately to achieve the best clinical results.
Call INNOV-ID is focused on investing in science and technology projects or companies in pre-seed, seed or early stage where the technology is still at a prototype, proof of concept or product market fit validation stage. It was launched in response to a request from the Portuguese government to support technology companies through the COVID-19 pandemic. It is managed by Portugal Ventures, a specialist in seed and early-stage investment in companies operating in digital, engineering and manufacturing, life sciences and tourism, in partnership with ANI, the Portuguese National Innovation Agency, financing specialist PME Investimentos and StartUp Portugal.
InSignals' first product is aimed at Parkinson's disease, and has already undergone three clinical studies involving 59 patients. Increased muscle rigidity is one of the key symptoms of the disease and is often treated by implanting deep brain stimulation electrodes when drugs no longer have an effect. InSignals' devices have shown they could help neurologists and neurosurgeons assess rigidity more objectively and place implants more accurately.
Doctors evaluate wrist rigidity during surgery to decide the optimum position for an implant. In some hospitals, two trained surgeons are required to make a judgement by manually manipulating the patient's wrist. This means evaluation can be biased by the physicians' experience and perception. It can also pose difficulties for younger specialists being trained in the procedure.
Other systems designed to provide objective and quantitative evaluation are complicated to set up and are impractical for use during surgical procedures. InSignals' device is easy to set up and use and is currently the only one providing real-time measurements.
Potential applications include helping pharmaceutical companies monitor or assess the impact of new or approved drugs in rigidity reduction during clinical trials.
InSignals was established to commercialise the work of
InSignals Neurotech co-Founder
Frontier IP Chief Executive Officer
ENQUIRIES
|
Frontier IP Group Plc |
T: 020 7332 2338 |
|
Company website: www.frontierip.co.uk |
M: 07464 546 025 |
|
Allenby Capital Limited (Nominated Adviser) |
T: 0203 328 5656 |
|
|
|
ABout frontier IP
Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of hands-on commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology is validated and meets real world demands and needs.
The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.
ABOUT INESC TEC
INESC TEC is a research institution with 35 years of experience in R&D and technology transfer in Computer Science, Industrial and Systems Engineering, Networked Intelligent Systems, and Power and Energy. With 350 doctorates among 700 researchers, INESC TEC aggregates 13 centres with complementary competences that are focused on the international market and has a patent portfolio of 23 patent families in ICT and medical technologies.
The institution drives the research results to their valorisation and adoption through technology transfer processes, from licensing to collaborative development, advanced consulting and training or spin-off launching.
ABOUT PorTugal Ventures
Portugal Ventures, a venture capital firm that is part of the Banco Português de Fomento group, currently manages
ABOUT REACH ANNOUNCEMENTS
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE